Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1831169 + Anti-PD1 mAb in Japanese Patients With Advanced/Metastatic Solid Tumours
NCT07176975Phase 1Suspended
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2027
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of VSV-GP in solid tumor (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Dose Limiting Toxicities at 6 weeks. Planned start Aug 2027; status: suspended.
02
Drugs
VSV-GP
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07176975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07176975.